Zevra Seeks FDA Authorization to Investigate KP1077 for Narcolepsy
KP1077 is currently being evaluated in a phase 2 clinical trial for the treatment of idiopathic hypersomnia.
Read More
Author: Alyx Arnett
Idorsia Urges DEA to De-schedule DORA Class of Insomnia Medications
The Schedule IV classification of the DORA class puts them in the same classification as benzodiazepines and Z-drugs; however, the DORA class works differently to treat insomnia and has a low potential for abuse, according to Idorsia.
Read More
FDA Evaluates ‘Safety Concerns’ Over Dental Devices Featured in KHN-CBS Investigation
The FDA says it’s aware of reports of serious complications linked to the devices—which are purported to treat certain conditions including sleep apnea—and asked that patients and healthcare providers report any complications.
Read More
How a Night of Poor Sleep Can Affect Your Next Day at Work—and Four Ways to Function Better
Survey findings reveal the negative impact of sleep deprivation on employee performance, including increasing the likelihood of engaging in unethical behavior.
Read More
Infant Supine Sleep System Gets FDA De Novo Approval
The baby bed is designed to keep sleeping babies positioned on the back—a position known to lower the risk of sudden infant death syndrome.
Read More